Key result
Blood type O, advanced age, history of peptic ulcer, and concomitant NSAID use independently increased the risk of peptic ulcer in low-dose aspirin users (ORs 2.1, 3.1, 27.6, and 2.9).
Why the study?
What are the genetic and clinical risk factors for developing peptic ulcer during cardiovascular prophylaxis with low-dose aspirin?
Case-Control (n=220)
What are the genetic and clinical risk factors for developing peptic ulcer during cardiovascular prophylaxis with low-dose aspirin?
Effect estimate: OR 2.1, 3.1, 27.6, and 2.9 respectively
Blood type O, advanced age, prior peptic ulcer, and concomitant NSAID use independently predict peptic ulcer development in patients taking low-dose aspirin for cardiovascular prophylaxis, while the COX-1 T-1676C polymorphism does not.
COX-1 T-1676C polymorphism is not a risk factor for aspirin ulcers; leaves open whether genotyping improves risk stratification beyond clinical factors.
AIMS: To investigate the impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter, and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin. METHODS: In a case-control study including 111 low-dose aspirin users with peptic ulcers and 109 controls (asymptomatic aspirin users), the polymorphism (T-1676C) of the COX-1 gene promoter was genotyped, and blood type, H pylori status, and clinical factors were assessed. RESULTS: Univariate analysis showed no significant differences in genotype frequencies of the COX-1 gene at position -1676 between the peptic ulcer group and control group. Multivariate analysis revealed that blood type O, advanced age, history of peptic ulcer, and concomitant use of NSAID were the independent risk factors for the development of peptic ulcer with the odds ratios of the 2.1, 3.1, 27.6, and 2.9, respectively. CONCLUSION: The C-1676T polymorphism in the COX-1 gene promoter is not a risk factor for ulcer formation during treatment with low-dose aspirin. Blood type O, advanced age, history of peptic ulcer, and concomitant use of NSAID are of independent significance in predicting peptic ulcer development during treatment with low-dose aspirin.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2014) conducted a case-control in Peptic ulcer during cardiovascular prophylaxis with low-dose aspirin (n=220). Blood type O, advanced age, history of peptic ulcer, and concomitant NSAID use vs. Absence of these risk factors was evaluated on Development of peptic ulcer (OR 2.1, 3.1, 27.6, and 2.9 respectively). Blood type O, advanced age, history of peptic ulcer, and concomitant NSAID use independently increased the risk of peptic ulcer in low-dose aspirin users (ORs 2.1, 3.1, 27.6, and 2.9).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: